Bristol-Myers Squibb Company Ce
Price Action
Technical Summary
STAGE 2 UPTRENDBristol-Myers Squibb Company Ce is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings growth of 9% provides fundamental context to the price action. Investors should exercise caution due to high volatility (238% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $0.09 | +20.88% | ABOVE |
| 50 SMA | $0.11 | +2.80% | ABOVE |
| 100 SMA | $0.10 | +6.49% | ABOVE |
| 150 SMA | $0.08 | +37.84% | ABOVE |
| 200 SMA | $0.07 | +61.29% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CELG-RI in an uptrend right now?
CELG-RI has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, CELG-RI is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is CELG-RI overbought or oversold?
CELG-RI's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.
Is CELG-RI outperforming the market?
CELG-RI has a Relative Strength (RS) Rating of 92 out of 99. Yes, CELG-RI is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is CELG-RI in its 52-week range?
CELG-RI is trading at $0.11, which is 40% of its 52-week high ($0.27) and 35% above its 52-week low ($0.02).
How volatile is CELG-RI?
CELG-RI has a Beta of -0.37 and 52-week volatility of 238%. It's less volatile than the S&P 500 - generally more stable.